Cargando…

Manganese is critical for antitumor immune responses via cGAS-STING and improves the efficacy of clinical immunotherapy

CD8(+) T cell-mediated cancer clearance is often suppressed by the interaction between inhibitory molecules like PD-1 and PD-L1, an interaction acts like brakes to prevent T cell overreaction under normal conditions but is exploited by tumor cells to escape the immune surveillance. Immune checkpoint...

Descripción completa

Detalles Bibliográficos
Autores principales: Lv, Mengze, Chen, Meixia, Zhang, Rui, Zhang, Wen, Wang, Chenguang, Zhang, Yan, Wei, Xiaoming, Guan, Yukun, Liu, Jiejie, Feng, Kaichao, Jing, Miao, Wang, Xurui, Liu, Yun-Cai, Mei, Qian, Han, Weidong, Jiang, Zhengfan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Singapore 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7785004/
https://www.ncbi.nlm.nih.gov/pubmed/32839553
http://dx.doi.org/10.1038/s41422-020-00395-4
_version_ 1783632375815602176
author Lv, Mengze
Chen, Meixia
Zhang, Rui
Zhang, Wen
Wang, Chenguang
Zhang, Yan
Wei, Xiaoming
Guan, Yukun
Liu, Jiejie
Feng, Kaichao
Jing, Miao
Wang, Xurui
Liu, Yun-Cai
Mei, Qian
Han, Weidong
Jiang, Zhengfan
author_facet Lv, Mengze
Chen, Meixia
Zhang, Rui
Zhang, Wen
Wang, Chenguang
Zhang, Yan
Wei, Xiaoming
Guan, Yukun
Liu, Jiejie
Feng, Kaichao
Jing, Miao
Wang, Xurui
Liu, Yun-Cai
Mei, Qian
Han, Weidong
Jiang, Zhengfan
author_sort Lv, Mengze
collection PubMed
description CD8(+) T cell-mediated cancer clearance is often suppressed by the interaction between inhibitory molecules like PD-1 and PD-L1, an interaction acts like brakes to prevent T cell overreaction under normal conditions but is exploited by tumor cells to escape the immune surveillance. Immune checkpoint inhibitors have revolutionized cancer therapeutics by removing such brakes. Unfortunately, only a minority of cancer patients respond to immunotherapies presumably due to inadequate immunity. Antitumor immunity depends on the activation of the cGAS-STING pathway, as STING-deficient mice fail to stimulate tumor-infiltrating dendritic cells (DCs) to activate CD8(+) T cells. STING agonists also enhance natural killer (NK) cells to mediate the clearance of CD8(+) T cell-resistant tumors. Therefore STING agonists have been intensively sought after. We previously discovered that manganese (Mn) is indispensable for the host defense against cytosolic dsDNA by activating cGAS-STING. Here we report that Mn is also essential in innate immune sensing of tumors and enhances adaptive immune responses against tumors. Mn-insufficient mice had significantly enhanced tumor growth and metastasis, with greatly reduced tumor-infiltrating CD8(+) T cells. Mechanically, Mn(2+) promoted DC and macrophage maturation and tumor-specific antigen presentation, augmented CD8(+) T cell differentiation, activation and NK cell activation, and increased memory CD8(+) T cells. Combining Mn(2+) with immune checkpoint inhibition synergistically boosted antitumor efficacies and reduced the anti-PD-1 antibody dosage required in mice. Importantly, a completed phase 1 clinical trial with the combined regimen of Mn(2+) and anti-PD-1 antibody showed promising efficacy, exhibiting type I IFN induction, manageable safety and revived responses to immunotherapy in most patients with advanced metastatic solid tumors. We propose that this combination strategy warrants further clinical translation.
format Online
Article
Text
id pubmed-7785004
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Springer Singapore
record_format MEDLINE/PubMed
spelling pubmed-77850042021-01-14 Manganese is critical for antitumor immune responses via cGAS-STING and improves the efficacy of clinical immunotherapy Lv, Mengze Chen, Meixia Zhang, Rui Zhang, Wen Wang, Chenguang Zhang, Yan Wei, Xiaoming Guan, Yukun Liu, Jiejie Feng, Kaichao Jing, Miao Wang, Xurui Liu, Yun-Cai Mei, Qian Han, Weidong Jiang, Zhengfan Cell Res Article CD8(+) T cell-mediated cancer clearance is often suppressed by the interaction between inhibitory molecules like PD-1 and PD-L1, an interaction acts like brakes to prevent T cell overreaction under normal conditions but is exploited by tumor cells to escape the immune surveillance. Immune checkpoint inhibitors have revolutionized cancer therapeutics by removing such brakes. Unfortunately, only a minority of cancer patients respond to immunotherapies presumably due to inadequate immunity. Antitumor immunity depends on the activation of the cGAS-STING pathway, as STING-deficient mice fail to stimulate tumor-infiltrating dendritic cells (DCs) to activate CD8(+) T cells. STING agonists also enhance natural killer (NK) cells to mediate the clearance of CD8(+) T cell-resistant tumors. Therefore STING agonists have been intensively sought after. We previously discovered that manganese (Mn) is indispensable for the host defense against cytosolic dsDNA by activating cGAS-STING. Here we report that Mn is also essential in innate immune sensing of tumors and enhances adaptive immune responses against tumors. Mn-insufficient mice had significantly enhanced tumor growth and metastasis, with greatly reduced tumor-infiltrating CD8(+) T cells. Mechanically, Mn(2+) promoted DC and macrophage maturation and tumor-specific antigen presentation, augmented CD8(+) T cell differentiation, activation and NK cell activation, and increased memory CD8(+) T cells. Combining Mn(2+) with immune checkpoint inhibition synergistically boosted antitumor efficacies and reduced the anti-PD-1 antibody dosage required in mice. Importantly, a completed phase 1 clinical trial with the combined regimen of Mn(2+) and anti-PD-1 antibody showed promising efficacy, exhibiting type I IFN induction, manageable safety and revived responses to immunotherapy in most patients with advanced metastatic solid tumors. We propose that this combination strategy warrants further clinical translation. Springer Singapore 2020-08-24 2020-11 /pmc/articles/PMC7785004/ /pubmed/32839553 http://dx.doi.org/10.1038/s41422-020-00395-4 Text en © The Author(s) 2020 Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.
spellingShingle Article
Lv, Mengze
Chen, Meixia
Zhang, Rui
Zhang, Wen
Wang, Chenguang
Zhang, Yan
Wei, Xiaoming
Guan, Yukun
Liu, Jiejie
Feng, Kaichao
Jing, Miao
Wang, Xurui
Liu, Yun-Cai
Mei, Qian
Han, Weidong
Jiang, Zhengfan
Manganese is critical for antitumor immune responses via cGAS-STING and improves the efficacy of clinical immunotherapy
title Manganese is critical for antitumor immune responses via cGAS-STING and improves the efficacy of clinical immunotherapy
title_full Manganese is critical for antitumor immune responses via cGAS-STING and improves the efficacy of clinical immunotherapy
title_fullStr Manganese is critical for antitumor immune responses via cGAS-STING and improves the efficacy of clinical immunotherapy
title_full_unstemmed Manganese is critical for antitumor immune responses via cGAS-STING and improves the efficacy of clinical immunotherapy
title_short Manganese is critical for antitumor immune responses via cGAS-STING and improves the efficacy of clinical immunotherapy
title_sort manganese is critical for antitumor immune responses via cgas-sting and improves the efficacy of clinical immunotherapy
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7785004/
https://www.ncbi.nlm.nih.gov/pubmed/32839553
http://dx.doi.org/10.1038/s41422-020-00395-4
work_keys_str_mv AT lvmengze manganeseiscriticalforantitumorimmuneresponsesviacgasstingandimprovestheefficacyofclinicalimmunotherapy
AT chenmeixia manganeseiscriticalforantitumorimmuneresponsesviacgasstingandimprovestheefficacyofclinicalimmunotherapy
AT zhangrui manganeseiscriticalforantitumorimmuneresponsesviacgasstingandimprovestheefficacyofclinicalimmunotherapy
AT zhangwen manganeseiscriticalforantitumorimmuneresponsesviacgasstingandimprovestheefficacyofclinicalimmunotherapy
AT wangchenguang manganeseiscriticalforantitumorimmuneresponsesviacgasstingandimprovestheefficacyofclinicalimmunotherapy
AT zhangyan manganeseiscriticalforantitumorimmuneresponsesviacgasstingandimprovestheefficacyofclinicalimmunotherapy
AT weixiaoming manganeseiscriticalforantitumorimmuneresponsesviacgasstingandimprovestheefficacyofclinicalimmunotherapy
AT guanyukun manganeseiscriticalforantitumorimmuneresponsesviacgasstingandimprovestheefficacyofclinicalimmunotherapy
AT liujiejie manganeseiscriticalforantitumorimmuneresponsesviacgasstingandimprovestheefficacyofclinicalimmunotherapy
AT fengkaichao manganeseiscriticalforantitumorimmuneresponsesviacgasstingandimprovestheefficacyofclinicalimmunotherapy
AT jingmiao manganeseiscriticalforantitumorimmuneresponsesviacgasstingandimprovestheefficacyofclinicalimmunotherapy
AT wangxurui manganeseiscriticalforantitumorimmuneresponsesviacgasstingandimprovestheefficacyofclinicalimmunotherapy
AT liuyuncai manganeseiscriticalforantitumorimmuneresponsesviacgasstingandimprovestheefficacyofclinicalimmunotherapy
AT meiqian manganeseiscriticalforantitumorimmuneresponsesviacgasstingandimprovestheefficacyofclinicalimmunotherapy
AT hanweidong manganeseiscriticalforantitumorimmuneresponsesviacgasstingandimprovestheefficacyofclinicalimmunotherapy
AT jiangzhengfan manganeseiscriticalforantitumorimmuneresponsesviacgasstingandimprovestheefficacyofclinicalimmunotherapy